Giovanni B Frisoni, Cristina Festari, Federico Massa, Matteo Cotta Ramusino, Stefania Orini, Dag Aarsland, Federica Agosta, Claudio Babiloni, Barbara Borroni, Stefano F Cappa, Kristian S Frederiksen, Lutz Froelich, Valentina Garibotto, Alexander Haliassos, Frank Jessen, Anita Kamondi, Roy Pc Kessels, Silvia D Morbelli, John T O'Brien, Markus Otto, Armand Perret-Liaudet, Francesca B Pizzini, Mathieu Vandenbulcke, Ritva Vanninen, Frans Verhey, Meike W Vernooij, Tarek Yousry, Mercè Boada Rovira, Bruno Dubois, Jean Georges, Oskar Hansson, Craig W Ritchie, Philip Scheltens, Wiesje M van der Flier, Flavio Nobili
The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease emphasises the need for consensus recommendations on the rational use of biomarkers to diagnose people with suspected neurocognitive disorders in memory clinics. Most available recommendations and guidelines are either disease-centred or biomarker-centred. A European multidisciplinary taskforce consisting of 22 experts from 11 European scientific societies set out to define the first patient-centred diagnostic workflow that aims to prioritise testing for available biomarkers in individuals attending memory clinics...
March 2024: Lancet Neurology